Rates of prostate-specific antigen testing in general practice in England and Wales in asymptomatic and symptomatic patients: a cross-sectional study

BJU International
Jane MeliaContributors in the participating laboratories

Abstract

To assess the rate of prostate-specific antigen (PSA) testing for prostate cancer in general practice in asymptomatic and symptomatic patients. The cross-sectional study took place in England and Wales, was population-based and covered 469 159 men aged 45-84 years. Pathology data on PSA tests requested between 19 November 1999 and 31 May 2002 by general practitioners (GPs) were provided by 28 pathology laboratories. The practices recorded reasons for the tests between 1 December 2001 and 31 May 2002. In all, 391 practices in which all GP partners participated were included in the analyses. The overall annual rate of testing in men with no previous diagnosis of prostate cancer was estimated to be 6%, of which the annual rates of asymptomatic, symptomatic and re-testing were 2.0%, 2.8% and 1.2%, respectively, after adjusting for missing values. The rate decreased with increasing social deprivation, and with increasing proportions of black and Asian populations. The overall rate of PSA testing increased significantly from 1999 to 2002. If the recommendations of the National Health Service Prostate Cancer Risk Management Programme were applied, 14% of asymptomatic tests and 23% of symptomatic tests would have led to a referral. As ...Continue Reading

References

Nov 1, 1992·British Journal of Cancer·A E GrulichM G Marmot
Sep 5, 2001·British Journal of Cancer·J Melia, S Moss
Oct 6, 2001·BMJ : British Medical Journal·J L DonovanF C Hamdy
Dec 6, 2001·Annals of Clinical Biochemistry·A M WardF C Hamdy
Jan 5, 2002·International Journal of Cancer. Journal International Du Cancer·Harry J de KoningUNKNOWN International Prostate Cancer Screening Trials Evaluation Group
May 17, 2002·The Journal of Pathology·M C ParkinsonJ Melia
Mar 31, 2004·BJU International·A GavinL J Murray

❮ Previous
Next ❯

Citations

Jun 30, 2009·Irish Journal of Medical Science·F J DrummondH Comber
Jul 7, 2005·Clinical Oncology : a Journal of the Royal College of Radiologists·C Parker, J Melia
Nov 28, 2009·Family Practice·Jane MeliaDerek Coleman
Jul 13, 2011·Journal of Public Health·J M BarbiereG Lyratzopoulos
Jul 1, 2009·Journal of Medical Screening·Nora PashayanStephen W Duffy
Mar 20, 2012·European Urology·Melissa M CenterFreddie Bray
Nov 5, 2010·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J A LaneJ L Donovan
May 18, 2010·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·R G H M CremersL A L M Kiemeney
Apr 22, 2008·The Lancet Oncology·Simon M CollinJenny Donovan
Sep 11, 2007·European Urology·Richard J Bryant, Freddie C Hamdy
Apr 6, 2007·Clinica Chimica Acta; International Journal of Clinical Chemistry·Catharine M Sturgeon, Andrew R Ellis
May 6, 2009·International Journal of Cancer. Journal International Du Cancer·Nina Føns JohnsenElio Riboli
Dec 6, 2008·Cancer·Sherri Sheinfeld GorinJane Wardle
Dec 23, 2008·Molecular Nutrition & Food Research·Peter D BaadeLauren J Krnjacki
Jun 19, 2007·International Journal of Andrology·R H JackH Møller
Jun 11, 2008·BJU International·Chris MetcalfeUNKNOWN PROCESS Study Group
Dec 15, 2010·International Journal of Cancer. Journal International Du Cancer·Håkan JonssonPär Stattin
Mar 19, 2016·International Journal of Clinical Practice·S MossM Kirby
Apr 12, 2016·European Urology·Alison J PriceUNKNOWN Endogenous Hormones, Nutritional Biomarkers, and Prostate Cancer Collaborative Group
Aug 19, 2014·Clinical Biochemistry·William GordayChristopher Naugler
Oct 11, 2016·European Urology·Thomas J JohnstonUNKNOWN ProtecT study group
Sep 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Suzie J OttoHarry J de Koning
Apr 8, 2010·British Journal of Cancer·R C MacefieldUNKNOWN ProtecT Study Group
Mar 20, 2008·British Journal of Cancer·J MeliaS Moss

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.